IDIBAPS participates in European Network on antibiotic resistances and hospital infections

This release is also available in Spanish.

The MOSAR project (Mastering hOSpital Antimicrobial Resistance and its spread into the community) is the first European-scale work devoted to the control and study of antimicrobial resistance in hospitals. MOSAR is coordinated by the Institut national de la sant e de la recherche mdicale (INSERM, Christian Brun-Buisson, unit 657 "Pharmaco-epidemiology and assessment of the impact of health products on populations"), and has about 20 public and private laboratories, and more than 50 hospitals in Europe and Israel. IDIBAPS-Hospital Clnic is the only nationwide representative of the network, and has the participation of the group of Dr. Jordi Vila, head of the Bacteriology Unit of Hospital Clnic, and member of the Public health, epidemiology and international health group of IDIBAPS.

The appearance and spread of resistant bacteria is one of the most alarming events of the last fifty years. This problem is aggravated by the slow pace of design of innovative antibiotics during the last 20 years. This phenomenon is most visible in the framework of hospitals, but general population is also affected, since exchanges between both sectors are increasingly rapid and numerous. Research on the transmission dynamics of four types of microorganisms (methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococcus, Acinetobacter spp. and extended-spectrum-lactamase-producing Enterobacter) will allow a design of strategies to control the appearance and spread of these multiresistant microorganisms.

MOSAR will structure the network in a platform of services in order to establish industrial collaborations with the large private institutions of this field. All MOSAR members are highly involved in the fight against bacterial resistances. MOSAR is a 5-year integrated project

Contact: lex Argem
IDIBAPS - Institut d'Investigacions Biomdiques August Pi i Sunyer

Page: 1 2

Related biology news :

1. Fundacin BBVA and IDIBAPS reassess the intermittent treatment efficiency against malaria
2. Biodesign Institute participates in first-of-its-kind coyote disaster preparedness drill
3. Yale participates in global human genome initiative
4. European Science Foundations Forward Look reaches out beyond the endless frontiers
5. The UAB heads a European research project on proteases and pathological processes
6. Journalists can register now for ECCO 14 -- the European Cancer Conference
7. Climate changes brews trouble for marine life in European Seas, Marine Board-ESF report says
8. Early Europeans unable to stomach milk
9. European launch of International Polar Year 2007-2008
10. European approval of HIV drug darunavir will provide a potent new option with Fuzeon
11. European launch of International Polar Year 2007-2008

Post Your Comments:

(Date:5/26/2019)... ... ... Zolgensma (Novartis, AveXis), an AAV-delivered gene therapy used to treat spinal muscular ... States by the Food and Drug Administration today. , The treatment is ... the United States and the second-ever approved treatment for SMA. , FDA granted priority ...
(Date:5/23/2019)... ... May 23, 2019 , ... ... for sales and service organizations, today announced its inclusion in DMG Consulting’s ... as the intelligent virtual agent (IVA) market share leader, based on number of ...
(Date:5/21/2019)... ... ... Suvoda LLC , a SaaS provider of Interactive Response Technology (IRT) ... Inc. Magazine’s Best Workplaces for 2019, Inc.’s fourth annual ranking of the fast-growing private ... the newsstands on May 28, is the result of a comprehensive measurement of private ...
Breaking Biology News(10 mins):
(Date:5/7/2019)... ... May 06, 2019 , ... ... the growing number of repositories being asked to store cellular products being ... team of contributors who are world leaders, who have shared their expertise in ...
(Date:5/2/2019)... , ... April 30, 2019 ... ... International Organization for Standardization ISO 9001:2015 standard, REPROCELL USA Inc. has demonstrated ... requirements. In addition, REPROCELL USA Inc. aims to enhance customer satisfaction through ...
(Date:5/2/2019)... ... May 02, 2019 , ... Researchers from ... documenting discrepancies between U.S. insurer policies for genetic testing and the 2019 National ... breast and ovarian cancer (HBOC). , Jill S. Dolinsky, director of ...
(Date:4/25/2019)... ... April 24, 2019 , ... Inference Solutions , a ... today announced global availability of Inference Studio’s latest version, which makes it easier ... harness the power of Google’s Contact Center AI (CCAI). , As ...
Breaking Biology Technology:
Cached News: